Cargando…

Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen

BACKGROUND: Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common recessive ataxia, results fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Calmels, Nadège, Seznec, Hervé, Villa, Pascal, Reutenauer, Laurence, Hibert, Marcel, Haiech, Jacques, Rustin, Pierre, Koenig, Michel, Puccio, Hélène
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744904/
https://www.ncbi.nlm.nih.gov/pubmed/19703283
http://dx.doi.org/10.1186/1471-2377-9-46
_version_ 1782171935445090304
author Calmels, Nadège
Seznec, Hervé
Villa, Pascal
Reutenauer, Laurence
Hibert, Marcel
Haiech, Jacques
Rustin, Pierre
Koenig, Michel
Puccio, Hélène
author_facet Calmels, Nadège
Seznec, Hervé
Villa, Pascal
Reutenauer, Laurence
Hibert, Marcel
Haiech, Jacques
Rustin, Pierre
Koenig, Michel
Puccio, Hélène
author_sort Calmels, Nadège
collection PubMed
description BACKGROUND: Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common recessive ataxia, results from a generalized deficiency of mitochondrial and cytosolic iron-sulfur cluster (ISC) proteins activity, due to a partial loss of frataxin function, a mitochondrial protein proposed to function as an iron-chaperone for ISC biosynthesis. In the absence of measurable catalytic function for frataxin, a cell-based assay is required for HTS assay. METHODS: Using a targeted ribozyme strategy in murine fibroblasts, we have developed a cellular model with strongly reduced levels of frataxin. We have used this model to screen the Prestwick Chemical Library, a collection of one thousand off-patent drugs, for potential molecules for FRDA. RESULTS: The frataxin deficient cell lines exhibit a proliferation defect, associated with an ISC enzyme deficit. Using the growth defect as end-point criteria, we screened the Prestwick Chemical Library. However no molecule presented a significant and reproducible effect on the proliferation rate of frataxin deficient cells. Moreover over numerous passages, the antisense ribozyme fibroblast cell lines revealed an increase in frataxin residual level associated with the normalization of ISC enzyme activities. However, the ribozyme cell lines and FRDA patient cells presented an increase in Mthfd2 transcript, a mitochondrial enzyme that was previously shown to be upregulated at very early stages of the pathogenesis in the cardiac mouse model. CONCLUSION: Although no active hit has been identified, the present study demonstrates the feasibility of using a cell-based approach to HTS for FRDA. Furthermore, it highlights the difficulty in the development of a stable frataxin-deficient cell model, an essential condition for productive HTS in the future.
format Text
id pubmed-2744904
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27449042009-09-16 Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen Calmels, Nadège Seznec, Hervé Villa, Pascal Reutenauer, Laurence Hibert, Marcel Haiech, Jacques Rustin, Pierre Koenig, Michel Puccio, Hélène BMC Neurol Research Article BACKGROUND: Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common recessive ataxia, results from a generalized deficiency of mitochondrial and cytosolic iron-sulfur cluster (ISC) proteins activity, due to a partial loss of frataxin function, a mitochondrial protein proposed to function as an iron-chaperone for ISC biosynthesis. In the absence of measurable catalytic function for frataxin, a cell-based assay is required for HTS assay. METHODS: Using a targeted ribozyme strategy in murine fibroblasts, we have developed a cellular model with strongly reduced levels of frataxin. We have used this model to screen the Prestwick Chemical Library, a collection of one thousand off-patent drugs, for potential molecules for FRDA. RESULTS: The frataxin deficient cell lines exhibit a proliferation defect, associated with an ISC enzyme deficit. Using the growth defect as end-point criteria, we screened the Prestwick Chemical Library. However no molecule presented a significant and reproducible effect on the proliferation rate of frataxin deficient cells. Moreover over numerous passages, the antisense ribozyme fibroblast cell lines revealed an increase in frataxin residual level associated with the normalization of ISC enzyme activities. However, the ribozyme cell lines and FRDA patient cells presented an increase in Mthfd2 transcript, a mitochondrial enzyme that was previously shown to be upregulated at very early stages of the pathogenesis in the cardiac mouse model. CONCLUSION: Although no active hit has been identified, the present study demonstrates the feasibility of using a cell-based approach to HTS for FRDA. Furthermore, it highlights the difficulty in the development of a stable frataxin-deficient cell model, an essential condition for productive HTS in the future. BioMed Central 2009-08-24 /pmc/articles/PMC2744904/ /pubmed/19703283 http://dx.doi.org/10.1186/1471-2377-9-46 Text en Copyright © 2009 Calmels et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Calmels, Nadège
Seznec, Hervé
Villa, Pascal
Reutenauer, Laurence
Hibert, Marcel
Haiech, Jacques
Rustin, Pierre
Koenig, Michel
Puccio, Hélène
Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title_full Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title_fullStr Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title_full_unstemmed Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title_short Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
title_sort limitations in a frataxin knockdown cell model for friedreich ataxia in a high-throughput drug screen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744904/
https://www.ncbi.nlm.nih.gov/pubmed/19703283
http://dx.doi.org/10.1186/1471-2377-9-46
work_keys_str_mv AT calmelsnadege limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT seznecherve limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT villapascal limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT reutenauerlaurence limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT hibertmarcel limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT haiechjacques limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT rustinpierre limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT koenigmichel limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen
AT pucciohelene limitationsinafrataxinknockdowncellmodelforfriedreichataxiainahighthroughputdrugscreen